信達生物(01801.HK)第三代肺癌靶向藥物奧壹新獲準上市

阿斯達克財經

昨天

信達生物(01801.HK) 公佈，第三代表皮生長因子受體“EGFR”酪氨酸激酶抑制劑（“TKI”）靶向藥物奧壹新(利厄替尼片)新藥上市申請獲中國國家藥品監督管理局批准，用於具有EGFR外顯子19缺失或外顯子21置換突變的局部晚期或復發轉移性非小細胞肺癌成人患者的一線治療。

2024年10月，公司與江蘇奧賽康就利厄替尼片在中國達成獨家商業化合作。目前，奧壹新已在中國獲批2項適應症。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2025-04-25 16:25。)

AASTOCKS新聞

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2530436586"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530436586\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2530436586?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220906114108815_s.jpg","is_english":false,"pubTime":"2025-04-27 18:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530436586","market":"hk","top_or_hot":-1,"title":"信達生物(01801.HK)第三代肺癌靶向藥物奧壹新獲準上市","media":"阿斯達克財經","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/01801\">信達生物</a>(01801.HK)<span> </span>公佈，第三代表皮生長因子受體“EGFR”酪氨酸激酶抑制劑（“TKI”）靶向藥物奧壹新(利厄替尼片)新藥上市申請獲中國國家藥品監督管理局批准，用於具有EGFR外顯子19缺失或外顯子21置換突變的局部晚期或復發轉移性非小細胞肺癌成人患者的一線治療。<br/><span></span><br/>2024年10月，公司與江蘇<a href=\"https://laohu8.com/S/002755\">奧賽康</a>就利厄替尼片在中國達成獨家商業化合作。目前，奧壹新已在中國獲批2項適應症。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2025-04-25 16:25。)<br/><br/></p><div></div>AASTOCKS新聞 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>信達生物(01801.HK)第三代肺癌靶向藥物奧壹新獲準上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n信達生物(01801.HK)第三代肺癌靶向藥物奧壹新獲準上市\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2025-04-27 18:12</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div> <span> <p><a href=\"https://laohu8.com/S/01801\">信達生物</a>(01801.HK)<span> </span>公佈，第三代表皮生長因子受體“EGFR”酪氨酸激酶抑制劑（“TKI”）靶向藥物奧壹新(利厄替尼片)新藥上市申請獲中國國家藥品監督管理局批准，用於具有EGFR外顯子19缺失或外顯子21置換突變的局部晚期或復發轉移性非小細胞肺癌成人患者的一線治療。<br/><span></span><br/>2024年10月，公司與江蘇<a href=\"https://laohu8.com/S/002755\">奧賽康</a>就利厄替尼片在中國達成獨家商業化合作。目前，奧壹新已在中國獲批2項適應症。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2025-04-25 16:25。)<br/><br/></p><div></div>AASTOCKS新聞 </span> </div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436137/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心資產","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436137/latest-news/AAFN","article_id":"2530436586","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220906114108815_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530436586","pubTimestamp":1745748720,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"信達生物(01801.HK) 公佈，第三代表皮生長因子受體“EGFR”酪氨酸激酶抑制劑（“TKI”）靶向藥物奧壹新(利厄替尼片)新藥上市申請獲中國國家藥品監督管理局批准，用於具有EGFR外顯子19缺失或外顯子21置換突變的局部晚期或復發轉移性非小細胞肺癌成人患者的一線治療。2024年10月，公司與江蘇奧賽康就利厄替尼片在中國達成獨家商業化合作。目前，奧壹新已在中國獲批2項適應症。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2025-04-25 16:25。)AASTOCKS新聞","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1589":"北水核心资产","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1583":"高瓴概念","01801":"信达生物","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC"},"translate_title":"Innovent Biologics (01801. HK) third-generation lung cancer targeted drug Aoyixin approved for marketing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"信達生物(01801.HK) 公佈，第三代表皮生長因子受體“EGFR”酪氨酸激酶抑制劑（“TKI”）靶向藥物奧壹新(利厄替尼片)新藥上市申請獲中國國家藥品監督管理局批准，用於具有EGFR外顯子19缺失或外顯子21置換突變的局部晚期或復發轉移性非小細胞肺癌成人患者的一線治療。2024年10月，公司與江蘇奧賽康就利厄替尼片在中國達成獨家商業化合作。目前，奧壹新已在中國獲批2項適應症。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2025-04-25 16:25。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}